Table 3.

Prescribed medications stratified by chronic kidney disease (CKD) before the exclusion of those intolerable to GDMT

Characteristic, n (%) unless specified otherwise	All (N = 171)	CKD		p-value
		No (n = 59)	Yes (n = 112)
Beta blockers (168/171)	149 (89%)	51 (86%)	98 (90%)	0.498
Bisoprolol	68 (40%)	25 (42%)	43 (39%)
Carvedilol	81 (48%)	26 (44%)	55 (50%)
ACEIs (168/171)	69 (41%)	28 (48%)	41 (38%)	0.183
Lisinopril	69 (41%)	28 (48%)	41 (38%)
ARBs (166/171)	28 (17%)	13 (22%)	15 (14%)	0.162
Irbesartan	18 (%)	9 (16%)	9 (8.3%)
Valsartan	10 (%)	4 (6.9%)	6 (5.6%)
Sacubitril/valsartan (166/171)	6 (3.6%)	2 (3.5%)	4 (3.7%)	1.000
RAS blockers (166/171)	102 (61%)	43 (74%)	59 (55%)	0.014
Hydralazine (166/171)	31 (17%)	2 (3.5%)	29 (27%)	<0.001
Oral nitrate (166/171)	31 (17%)	4 (6.9%)	27 (25%)	0.004
HYD/ISDN (166/171)	26 (16%)	2 (3.5%)	24 (22%)	0.001
RAS / HYD/ISDN (167/171)	128 (77%)	45 (78%)	83 (76%)	0.834
MRAs (166/171)	78 (47%)	35 (60%)	43 (40%)	0.012
Spironolactone	77 (47%)	35 (60%)	42 (39%)
Eplerenone	1 (<0.1%)	0	1 (0.1%)
Triple GDMT regimen (165/171)	67 (41%)	31 (54%)	36 (33%)	0.009
Frusemide	142 (83%)	47 (80%)	95 (85%)	0.393
Calcium channel blocker	17 (9.9%)	3 (5.1%)	14 (13%)	0.179
Clopidogrel	43 (25%)	16 (27%)	27 (24%)	0.666
Aspirin (166/171)	79 (48%)	19 (33%)	60 (56%)	0.004
Statins	113 (66%)	33 (56%)	80 (71%)	0.042

GDMT, guideline-directed medical therapy that include a beta blocker, a RAS blocker (or a hydralazine-nitrate combination), and an MRA; ACEIs, angiotensin-converting-enzyme inhibitors; ARBs, angiotensin receptor blockers; RAS, renin-angiotensin-system blockers; HYD/ISDN, hydralazine-nitrate combination; MRAs, mineralocorticoid receptor antagonist.

Column percentages might not add up to 100% due to rounding off.